2017
Usefulness of Myocardial Annular Velocity Change During Mental Stress to Predict Cardiovascular Outcome in Patients With Coronary Artery Disease (From the Responses of Mental Stress-Induced Myocardial Ischemia to Escitalopram Treatment Trial)
Alenezi F, Brummett BH, Boyle SH, Samad Z, Babyak MA, Alzaeim N, Wilson J, Romano MMD, Sun JL, Ersboll M, O'Connor CM, Velazquez EJ, Jiang W. Usefulness of Myocardial Annular Velocity Change During Mental Stress to Predict Cardiovascular Outcome in Patients With Coronary Artery Disease (From the Responses of Mental Stress-Induced Myocardial Ischemia to Escitalopram Treatment Trial). The American Journal Of Cardiology 2017, 120: 1495-1500. PMID: 28917493, DOI: 10.1016/j.amjcard.2017.07.039.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseStable coronary artery diseaseAdverse cardiovascular outcomesCardiovascular outcomesArtery diseaseNew York Heart Association functional class IMental stress-induced myocardial ischemiaStress-induced myocardial ischemiaNonfatal cardiovascular eventsFunctional class IMental stress testingCox regression modelMS-induced changesCardiovascular eventsCause mortalityUnplanned hospitalizationPrognostic factorsMean ageMyocardial ischemiaSystolic velocityAnnular velocityPatientsMental stressClass IMACEMental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients
Sun JL, Boyle SH, Samad Z, Babyak MA, Wilson JL, Kuhn C, Becker RC, Ortel TL, Williams RB, Rogers JG, O’Connor C, Velazquez EJ, Jiang W. Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients. European Journal Of Preventive Cardiology 2017, 24: 591-599. PMID: 28067532, PMCID: PMC6093615, DOI: 10.1177/2047487316686435.Peer-Reviewed Original ResearchMeSH KeywordsAgedCitalopramDisease-Free SurvivalFemaleHumansMaleMental HealthMiddle AgedMultivariate AnalysisMyocardial IschemiaProportional Hazards ModelsRisk AssessmentRisk FactorsSelective Serotonin Reuptake InhibitorsStress, PsychologicalStroke VolumeTime FactorsTreatment OutcomeVentricular Dysfunction, LeftVentricular Function, LeftConceptsMental stress-induced myocardial ischemiaMajor adverse cardiovascular eventsAdverse cardiovascular eventsLeft ventricular ejection fraction changeVentricular ejection fraction changeStable ischemic heart diseaseIschemic heart disease patientsLeft ventricular ejection fractionStress-induced myocardial ischemiaEjection fraction changesVentricular ejection fractionIschemic heart diseaseCardiovascular eventsHeart disease patientsMyocardial ischemiaEjection fractionStudy endpointDisease patientsHeart diseaseMental Stress–Induced Myocardial IschemiaStress-induced left ventricular dysfunctionFuture adverse cardiovascular eventsLeft ventricular dysfunctionHeart failure statusAssociation of indices
2016
Pulmonary function and adverse cardiovascular outcomes: Can cardiac function explain the link?
Peña M, Dunning A, Schulte PJ, Durheim MT, Kussin P, Checkley W, Velazquez EJ. Pulmonary function and adverse cardiovascular outcomes: Can cardiac function explain the link? Respiratory Medicine 2016, 121: 4-12. PMID: 27888991, DOI: 10.1016/j.rmed.2016.10.009.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionAdverse cardiovascular eventsPulmonary functionCause mortalityCardiovascular eventsCardiac hospitalizationCardiac functionDecreased LVEFNormal left ventricular ejection fractionSingle tertiary care medical centerTertiary care medical centerCox proportional hazards modelLeft heart remodelingRight heart dysfunctionAdverse cardiovascular outcomesRight ventricular functionTertiary care centerVentricular ejection fractionVentricular internal dimensionLeft heart structuresLeft heart sizeProportional hazards modelMultivariable linear regressionDecreased FVCCardiovascular outcomesCardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy
Weber MA, Bloch M, Bakris GL, Weir MR, Zappe DH, Dahlof B, Velazquez EJ, Pitt B, Basile JN, Jamerson K, Hua TA. Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. Journal Of Clinical Hypertension 2016, 18: 299-307. PMID: 27060568, PMCID: PMC8032014, DOI: 10.1111/jch.12816.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntihypertensive AgentsBlood PressureBlood Pressure DeterminationDiabetes Mellitus, Type 2Double-Blind MethodDrug Therapy, CombinationFemaleFollow-Up StudiesHumansHypertensionIncidenceMaleMyocardial InfarctionProspective StudiesRisk AssessmentRisk FactorsStrokeSurvival RateSystoleTreatment OutcomeUnited StatesConceptsSystolic blood pressureNondiabetic cohortCardiovascular outcomesPrimary endpointBlood pressurePrimary endpoint event rateTreatment systolic blood pressureEvent ratesAvoiding Cardiovascular EventsBlood pressure targetsDifferent SBP targetsFurther SBP reductionSystolic Hypertension (ACCOMPLISH) trialAdverse renal eventsComposite primary endpointTotal stroke ratesCV protectionNondiabetic patientsRenal considerationsRenal eventsSBP categoriesSBP reductionCardiovascular eventsHypertension trialsPressure targets
2014
Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study
Jiang W, Boyle SH, Ortel TL, Samad Z, Velazquez EJ, Harrison RW, Wilson J, Kuhn C, Williams RB, O’Connor C, Becker RC. Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study. American Heart Journal 2014, 169: 496-507.e1. PMID: 25819856, PMCID: PMC4382806, DOI: 10.1016/j.ahj.2014.12.002.Peer-Reviewed Original ResearchConceptsMental stress-induced myocardial ischemiaIschemic heart diseaseSerotonin transporter expressionMyocardial ischemiaPlatelet aggregationPlatelet hyperactivityNormal left ventricular responseStable ischemic heart diseaseStress-induced myocardial ischemiaMental stressTransporter expressionAcute coronary syndromeLeft ventricular responseMental stress testMental stress testingCombination of serotoninEligible patientsCardiovascular eventsCardiovascular prognosisCoronary syndromeVentricular responsePlatelet activityHeart diseaseTreatment studiesIschemiaClinical outcome as a function of the PR-interval—there is virtue in moderation: data from the Duke Databank for cardiovascular disease
Holmqvist F, Thomas KL, Broderick S, Ersbøll M, Singh D, Chiswell K, Shaw LK, Hegland DD, Velazquez EJ, Daubert JP. Clinical outcome as a function of the PR-interval—there is virtue in moderation: data from the Duke Databank for cardiovascular disease. EP Europace 2014, 17: 978-985. PMID: 25164430, DOI: 10.1093/europace/euu211.Peer-Reviewed Original ResearchConceptsCoronary heart diseaseHeart diseaseDuke University Medical CenterMajor cardiovascular outcomesMajor cardiovascular eventsNative coronary arteriesUniversity Medical CenterPR interval durationCV eventsCardiovascular eventsCardiovascular outcomesCause mortalityCoronary angiographyDuke DatabankClinical outcomesAtrial fibrillationPoor outcomeCoronary arterySignificant stenosisSinus rhythmCardiovascular diseaseMedical CenterHigh riskPatientsRelevant covariatesImpact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction A VALIANT Study (Valsartan In Acute Myocardial Infarction)
Lewis EF, Li Y, Pfeffer MA, Solomon SD, Weinfurt KP, Velazquez EJ, Califf RM, Rouleau JL, Kober L, White HD, Schulman KA, Reed SD. Impact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction A VALIANT Study (Valsartan In Acute Myocardial Infarction). JACC Heart Failure 2014, 2: 159-165. PMID: 24720924, DOI: 10.1016/j.jchf.2013.12.003.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsBundle-Branch BlockCaptoprilDeath, Sudden, CardiacDrug Therapy, CombinationFemaleHealth StatusHeart FailureHospitalizationHumansMaleMyocardial InfarctionQuality of LifeRecurrenceStrokeSurvivorsTetrazolesTreatment OutcomeValineValsartanConceptsNonfatal CV eventsEQ-5D assessmentCV eventsVisual analog scaleEQ-5D scoresCardiovascular eventsMyocardial infarctionEQ-5DBaseline EQ-5D scoresKillip class IINonfatal cardiovascular eventsHealth-related qualityLinear mixed-effects regression modelsQuality of lifeMixed effects regression modelsVALIANT studyWorse HRQLVAS scoresEjection fractionNonfatal eventsMI survivorsAnalog scaleVALIANT trialGeneric instrumentsPatients
2013
Depressive Symptoms and Mental Stress–Induced Myocardial Ischemia in Patients With Coronary Heart Disease
Boyle SH, Samad Z, Becker RC, Williams R, Kuhn C, Ortel TL, Kuchibhatla M, Prybol K, Rogers J, O’Connor C, Velazquez EJ, Jiang W. Depressive Symptoms and Mental Stress–Induced Myocardial Ischemia in Patients With Coronary Heart Disease. Psychosomatic Medicine 2013, 75: 822-831. PMID: 24163385, PMCID: PMC4378828, DOI: 10.1097/psy.0b013e3182a893ae.Peer-Reviewed Original ResearchConceptsMental stress-induced myocardial ischemiaCoronary heart diseaseLeft ventricular ejection fractionVentricular ejection fractionDepressive symptomsMyocardial ischemiaEjection fractionHeart diseaseMental Stress–Induced Myocardial IschemiaStress-induced myocardial ischemiaIschemic ST-segment changesBeck Depression Inventory-II scoresΒ-blocker withdrawalEpidemiologic Studies Depression ScaleFuture cardiovascular eventsMental stress testTreadmill exercise testST-segment changesWall motion abnormalitiesBeck Depression Inventory-IICardiovascular eventsII scoreTransthoracic echocardiographyAdult patientsUnadjusted analysesSystolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension
Weber MA, Bakris GL, Hester A, Weir MR, Hua TA, Zappe D, Dahlof B, Velazquez EJ, Pitt B, Jamerson K. Systolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension. The American Journal Of Medicine 2013, 126: 501-508. PMID: 23541376, DOI: 10.1016/j.amjmed.2013.01.007.Peer-Reviewed Original ResearchConceptsSystolic blood pressureHigh-risk hypertensive patientsPrimary end pointBlood pressure levelsSystolic bloodBlood pressureCardiovascular deathCardiovascular eventsCardiovascular outcomesCoronary eventsEnd pointHypertensive patientsMyocardial infarctionSystolic blood pressure levelsAvoiding Cardiovascular EventsSystolic Hypertension (ACCOMPLISH) trialTotal myocardial infarctionBlood pressure groupMajor cardiovascular eventsMean patient ageNonfatal myocardial infarctionCardiovascular event ratesRenal end pointsLower blood pressureTreatment of hypertension
2012
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial
Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. The Lancet 2012, 381: 537-545. PMID: 23219284, DOI: 10.1016/s0140-6736(12)61343-9.Peer-Reviewed Original ResearchConceptsCardiovascular event ratesBody mass indexNormal weightPrimary endpointObese patientsEvent ratesCardiovascular outcomesCardiovascular protectionHypertension treatmentObese individualsHigh-risk hypertensive patientsHigher cardiovascular event ratesNon-fatal myocardial infarctionAmlodipine-based therapyAvoiding Cardiovascular EventsPatient’s cardiovascular outcomeSuperior cardiovascular protectionSystolic Hypertension (ACCOMPLISH) trialPrimary event rateSingle-pill combinationPrevious clinical trialsNormal weight categoryCardiovascular deathCardiovascular eventsHypertension trials
2010
Efficacy and Duration of Benazepril Plus Amlodipine or Hydrochlorthiazide on 24-Hour Ambulatory Systolic Blood Pressure Control
Jamerson KA, Devereux R, Bakris GL, Dahlöf B, Pitt B, Velazquez EJ, Weir M, Kelly RY, Hua TA, Hester A, Weber MA. Efficacy and Duration of Benazepril Plus Amlodipine or Hydrochlorthiazide on 24-Hour Ambulatory Systolic Blood Pressure Control. Hypertension 2010, 57: 174-179. PMID: 21189401, DOI: 10.1161/hypertensionaha.110.159939.Peer-Reviewed Original ResearchConceptsAmbulatory blood pressure monitoringBlood pressure controlSystolic blood pressureBlood pressure monitoringBlood pressureCardiovascular eventsTreatment armsCombination therapyPressure monitoringBlood pressure control ratesClinic systolic blood pressureNighttime systolic blood pressurePressure controlRenin-angiotensin system blockersSystolic blood pressure controlAdditional risk predictionAngiotensin system blockersAvoiding Cardiovascular EventsCombination of benazeprilSystolic Hypertension (ACCOMPLISH) trialBlood pressure effectsNighttime blood pressureEffects of drugsYear 2ACCOMPLISH trialFatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: The VALsartan In Acute myocardial iNfarcTion Trial (VALIANT)
Shamshad F, Kenchaiah S, Finn PV, Soler-Soler J, McMurray JJ, Velazquez EJ, Maggioni AP, Califf RM, Swedberg K, Kober L, Belenkov Y, Varshavsky S, Pfeffer MA, Solomon SD, Investigators F. Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: The VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). American Heart Journal 2010, 160: 145-151. PMID: 20598985, DOI: 10.1016/j.ahj.2010.02.037.Peer-Reviewed Original ResearchConceptsQ-wave myocardial infarctionMyocardial infarctionMyocardial ruptureClinical end-point committeeHigh-risk myocardial infarctionAcute Myocardial Infarction trialEnd-point committeeNonfatal cardiovascular eventsPresence of hemopericardiumQualifying MIMyocardial Infarction trialHigh-risk patientsGlomerular filtration ratePost-MI patientsAcute myocardial infarctionInferior myocardial infarctionDirect surgical visualizationKillip classCardiovascular eventsDiuretic useOral anticoagulantsVentricular dysfunctionClinical characteristicsFatal complicationHeart failureCardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes
Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, Velazquez EJ, Dahlöf B, Kelly RY, Hua TA, Hester A, Pitt B, Investigators A. Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes. Journal Of The American College Of Cardiology 2010, 56: 77-85. PMID: 20620720, DOI: 10.1016/j.jacc.2010.02.046.Peer-Reviewed Original ResearchConceptsRenin-angiotensin system blockersDiabetic patientsCardiovascular eventsSystem blockersHigh riskPrimary end pointAcute clinical eventsUnexpected adverse eventsPrimary eventACCOMPLISH trialCoronary benefitNondiabetic patientsCardiovascular deathCoronary revascularizationDiabetes groupAdverse eventsBlood pressureHypertension therapyClinical eventsCombination therapyMyocardial infarctionPatientsDiabetesHypertensionEnd pointRenal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA, investigators F. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. The Lancet 2010, 375: 1173-1181. PMID: 20170948, DOI: 10.1016/s0140-6736(09)62100-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlbuminuriaAmlodipineAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzazepinesBlood PressureCalcium Channel BlockersCardiovascular DiseasesCreatinineDisease ProgressionDiureticsDouble-Blind MethodDrug CombinationsFemaleGlomerular Filtration RateHumansHydrochlorothiazideHypertensionKidney Failure, ChronicMaleMiddle AgedRisk FactorsConceptsChronic kidney diseaseKidney diseaseAmlodipine groupHydrochlorothiazide groupCardiovascular eventsCombination therapyHigh riskChronic kidney disease progressionEnd-stage renal diseaseFixed-dose combination therapyAvoiding Cardiovascular EventsBlood pressure goalsInitial antihypertensive therapyInitial antihypertensive treatmentPrespecified secondary analysisProgression of nephropathySystolic Hypertension (ACCOMPLISH) trialFrequent adverse eventsKidney disease progressionSerum creatinine concentrationTelephone-based interactive voice response systemAntihypertensive therapyAntihypertensive treatmentRenal outcomesCardiovascular morbidity
2009
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial
Piccini JP, Zhang M, Pieper K, Solomon SD, Al-Khatib SM, Van de Werf F, Pfeffer MA, McMurray JJ, Califf RM, Velazquez EJ. Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. European Heart Journal 2009, 31: 211-221. PMID: 19854729, DOI: 10.1093/eurheartj/ehp425.Peer-Reviewed Original ResearchConceptsSudden cardiac deathMyocardial infarctionInitial left ventricular ejection fractionRisk of SCDLeft ventricular ejection fractionHigher baseline heart rateBaseline creatinine clearanceBaseline clinical characteristicsRecurrent cardiovascular eventsPrior myocardial infarctionVentricular ejection fractionBaseline heart rateCox proportional hazardsCardiovascular eventsClinical characteristicsCreatinine clearanceCumulative incidenceCardiac deathEjection fractionEntire followRisk stratificationVALIANT trialPost-MIRisk stratifierLandmark analysisUsefulness of Beta Blockers in High-Risk Patients After Myocardial Infarction in Conjunction With Captopril and/or Valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] Trial)
Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA. Usefulness of Beta Blockers in High-Risk Patients After Myocardial Infarction in Conjunction With Captopril and/or Valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] Trial). The American Journal Of Cardiology 2009, 104: 151-157. PMID: 19576338, DOI: 10.1016/j.amjcard.2009.03.020.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdrenergic beta-AntagonistsAgedAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCaptoprilDrug Therapy, CombinationFemaleHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionProspective StudiesRisk AssessmentRisk FactorsSurvival AnalysisTetrazolesTreatment OutcomeValineValsartanConceptsBeta blockersHeart failureMyocardial infarctionBaseline characteristicsAcute Myocardial Infarction trialAngiotensin receptor blocker valsartanCombination of valsartanNonfatal cardiovascular eventsAngiotensin receptor blockersBeta-blocker useMyocardial Infarction trialVentricular systolic dysfunctionHigh-risk patientsRisk of deathSignificant survival advantageCardiovascular eventsSystolic dysfunctionVentricular dysfunctionVentricular functionSurvival advantageLower riskPatientsMortality rateBlockersValsartanChronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, Swedberg K, Pfeffer MA, McMurray JJ, Maggioni AP, Investigators F. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal Of Heart Failure 2009, 11: 292-298. PMID: 19176539, PMCID: PMC2645058, DOI: 10.1093/eurjhf/hfp001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsAtherosclerosisCause of DeathConfidence IntervalsDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleMiddle AgedMyocardial InfarctionOdds RatioPrognosisProportional Hazards ModelsProspective StudiesPulmonary Disease, Chronic ObstructiveSurvival RateTetrazolesTime FactorsValineValsartanConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseAcute Myocardial Infarction trialMyocardial Infarction trialPulmonary diseaseAcute myocardial infarctionAtherosclerotic eventsMyocardial infarctionIndependent predictorsCV outcomesHazard ratioNon-fatal clinical eventsNon-CV deathAdjusted hazard ratioMajor cardiovascular eventsHigh-risk patientsRisk of deathProportional hazards modelMode of deathMedian followCardiovascular eventsCause mortalityAirway diseaseMultivariate adjustmentUnadjusted risk
2008
Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients
Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. New England Journal Of Medicine 2008, 359: 2417-2428. PMID: 19052124, DOI: 10.1056/nejmoa0806182.Peer-Reviewed Original ResearchConceptsNonfatal myocardial infarctionCardiovascular eventsNonfatal strokeCardiovascular causesMyocardial infarctionHigh riskEnd pointDihydropyridine calcium channel blockerCurrent U.S. guidelinesComposite of deathDouble-blind trialPrimary end pointPrimary outcome eventSecondary end pointsHigh-risk patientsAbsolute risk reductionRelative risk reductionCalcium channel blockersCombination drug therapySudden cardiac arrestRisk reductionCoronary revascularizationStudy drugAdverse eventsBaseline characteristicsPrognostic Implications of Left Ventricular Mass and Geometry Following Myocardial Infarction The VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study
Verma A, Meris A, Skali H, Ghali JK, Arnold JM, Bourgoun M, Velazquez EJ, McMurray JJ, Kober L, Pfeffer MA, Califf RM, Solomon SD. Prognostic Implications of Left Ventricular Mass and Geometry Following Myocardial Infarction The VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovascular Imaging 2008, 1: 582-591. PMID: 19356485, DOI: 10.1016/j.jcmg.2008.05.012.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersCardiovascular DiseasesEuropeFemaleHeart VentriclesHumansHypertrophy, Left VentricularKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPredictive Value of TestsProportional Hazards ModelsRecurrenceRisk AssessmentRisk FactorsTetrazolesTime FactorsTreatment OutcomeUltrasonographyUnited StatesValineValsartanVentricular RemodelingConceptsLeft ventricular mass indexRelative wall thicknessHigh-risk myocardial infarctionAdverse cardiovascular eventsLeft ventricular massMyocardial infarctionLV geometryCardiovascular eventsConcentric remodelingEchocardiographic studyLV hypertrophyConcentric hypertrophyEccentric hypertrophyPrognostic implicationsVentricular massBaseline left ventricular mass indexMean left ventricular mass indexBaseline left ventricular massHigher relative wall thicknessBaseline LV massNonfatal cardiovascular outcomesAbnormal LV geometryComposite end pointVentricular mass indexConcentric LV hypertrophyComparison of Renal Function and Cardiovascular Risk Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus
Anavekar NS, Solomon SD, McMurray JJ, Maggioni A, Rouleau JL, Califf R, White H, Kober L, Velazquez E, Pfeffer MA. Comparison of Renal Function and Cardiovascular Risk Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus. The American Journal Of Cardiology 2008, 101: 925-929. PMID: 18359309, DOI: 10.1016/j.amjcard.2007.11.037.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionRenal dysfunctionRenal functionMyocardial infarctionCV outcomesDiabetes mellitusHigh-risk acute myocardial infarctionCox proportional modelingAdverse CV outcomesComposite cardiovascular eventsComposite end pointIndependent risk factorRenal Disease equationGlomerular filtration rateReduced renal functionBaseline creatinineCV eventsMean eGFRCardiovascular eventsCV diseaseCV riskVentricular dysfunctionCardiovascular riskHeart failureOverall mortality